⚕ GalenOps CRO console
← SITE011 (ITA)

SITE011-0289

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE011 (ITA) (Dr. Jansen) · consented 2023-02-07
Adverse events
9
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-03-22 (study day 34); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-14 (study day 57); relationship: N

moderate assessed 2026-08-18

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-05-06 (study day 79); relationship: N

moderate assessed 2026-08-18

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-05-17 (study day 90); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-07-19 (study day 153); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-28 (study day 193); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-09-01 (study day 197); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-09-18 (study day 214); relationship: N

severe serious assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-22 (study day 218); relationship: not assessed; serious criteria: hospitalization

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.